Cara Therapeutics Stock News

STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat Read more

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – Read more

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP Presentation will highlight opportunity for oral dif Read more

Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica Oral presentation will include Read more

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Read more

Here are seven steps to investing in the high-flying cannabis industry. Read more

Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? Read more

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia Read more

Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. Read more

As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are Read more

Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Read more

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Read more

STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives Read more

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Moderna Inc (NASDAQ: MRNA) submitt Read more

ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) --  Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that t Read more